Test score may predict which prostate cancer patients can safely skip combined therapy

Questions To Ask Your Health Care Provider

• What test will predict the risk of my cancer spreading?
• What are my options for treating prostate cancer?
• What side effects may be associated with my treatment?
• Is taking a combined- (or multi-) therapy approach necessary for my prostate cancer?

Open Clinical Trials

The following are studies enrolling people with early-stage prostate cancer.  

• NCT04404894: Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing. This registry will evaluate treatment selection for patients with newly diagnosed, localized prostate cancer following Prolaris testing—a risk estimating test. It will measure the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment, and clinical outcomes.
• NCT03697148: MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer. This study looks at how well a type of MRI known as multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. 
• NCT04396808: Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer. The study is looking at a new ways to use tumor testing and other tools to help patients understand their risk for recurrence and make decisions about their care after early-stage prostate cancer. 

A number of other clinical trials for patients with early-stage prostate can be found here.